Immunoregulatory molecules are master regulators of inflammation during the immune response  by de la Fuente, Hortensia et al.
FEBS Letters 586 (2012) 2897–2905journal homepage: www.FEBSLetters .orgReview
Immunoregulatory molecules are master regulators of inﬂammation
during the immune response
Hortensia de la Fuente 1, Danay Cibrián 1, Francisco Sánchez-Madrid ⇑
Centro Nacional de Investigaciones Cardiovasculares, Melchor Fernández Almagro, 3, 28029 Madrid, Spain
Servicio de Inmunología, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa, Diego de León, 62, 28006 Madrid, SpainOpen access under CC BY-NC-ND license.a r t i c l e i n f o
Article history:
Received 3 July 2012
Revised 10 July 2012
Accepted 11 July 2012
Available online 20 July 2012
Edited by Miguel De la Rosa, Felix Wieland
and Wilhelm Just
Keywords:
Immunoregulatory molecules
Tolerance
Treg
Inﬂammation
Autoimmune diseases0014-5793  2012 Federation of European Biochemic
http://dx.doi.org/10.1016/j.febslet.2012.07.032
⇑ Corresponding author at: Servicio de Inmunología
Princesa, Instituto de Investigación Sanitaria Princes
Madrid, Spain. Fax: +34 915202374.
E-mail address: fsanchez.hlpr@salud.madrid.org (F
1 These authors contribute equally to this work.a b s t r a c t
The balance between pro- and anti-inﬂammatory signalling is critical to maintain the immune
homeostasis under physiological conditions as well as for the control of inﬂammation in different
pathological settings. Recent progress in the signalling pathways that control this balance has led
to the development of novel therapeutic agents for diseases characterized by alterations in the acti-
vation/suppression of the immune response. Different molecules have a key role in the regulation of
the immune system, including the receptors PD-1 (Programmed cell Death 1), CTLA-4 (Cytotoxic T-
Lymphocyte Antigen 4) and galectins; or the intracellular enzyme IDO (indoleamine 2,3-dioxygen-
ase). In addition, other molecules as CD69, AhR (Aryl hydrocarbon Receptor), and GADD45 (Growth
Arrest and DNA Damage-inducible 45) family members, have emerged as potential targets for the
regulation of the activation/suppression balance of immune cells. This review offers a perspective
on well-characterized as well as emergent negative immune regulatory molecules in the context
of autoimmune inﬂammatory diseases.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
The magnitude of the immune response is determined by the
balance between positive and negative regulatory signals. Thus,
different immunosuppressive mechanisms are essential to main-
tain an effective level of immune response in different pathological
conditions without causing tissue damage, and also to preserve the
homeostasis under physiological conditions. Central tolerance
occurs in the thymus and is established by the deletion of auto-
reactive lymphocytes through the presentation of high afﬁnity
self-antigens [1]. However, a small proportion of auto-reactive T
lymphocytes are not deleted by the thymic negative selection
and these cells are able to reach the periphery. Since the immune
system is constantly exposed to self-antigens, several immune
strategies have been developed to avoid the generation of deleteri-
ous autoimmune responses, including the activation-induced cell
death, clonal anergy and immunosuppression mediated by regula-
tory T cells (Treg) [2]. During the last years, numerous efforts have
focused in understanding the mechanisms that regulate the
immune response. Novel pathways and new therapeutic agentsal Societies. Published by Elsevier
, Hospital Universitario de la
a, Diego de León 62, 28006
. Sánchez-Madrid).are currently under investigation for those pathological conditions
in which the normal balance between activation and suppression
of the immune response has failed [3]. Cell surface receptors, solu-
ble proteins and signalling molecules provide critical signals to
limit the immune response. Some of these molecules display a
well-characterized negative regulatory function of the inﬂamma-
tory response. Some examples are the cytokines TGF-beta and IL-
10 which, in addition to their direct effects on immune cells, also
control Treg cell differentiation and function [4,5].
Cell surface receptors such as members of the B7:CD28 family
also have key roles in the regulation of T cell activation and toler-
ance. These B7:CD28 pathways are not only essential second sig-
nals that promote T cell responses, but they also originate critical
negative second signals that limit T cell activation [6].
In addition to cell receptors and cytokines, a number of intracel-
lular molecules are also key components of tolerance mechanisms.
Some examples are the cytosolic enzyme indoleamine 2,3-dioxy-
genase (IDO) and SOCS signalling proteins, which are molecular
switches that provide negative regulation of cytokine signalling.
Recent studies in humans and animal models have revealed
new molecules involved in regulation on the immune response.
Some examples are galectins and CD69 as well as selected mem-
bers of the GADD45 family. These molecules are part of complex
signalling networks in which deregulation of one of these mole-
cules often alters the expression and/or function of others, tilting
the scales against tolerance.B.V. Open access under CC BY-NC-ND license. 
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neous group of molecules, which have in common that exert an
important role in the regulation of the inﬂammatory phenomenon
and the immune response.2. Leukocyte membrane receptor molecules: CTLA-4, PD-1, ICOS,
CD69 and galectins
2.1. The familiy of B7/CD28 immunoregulatory molecules
The CD28 family of receptors comprise at least four members
(CD28, CTLA-4, ICOS, and PD-1), which upon interaction with their
corresponding ligands are able to generate potent costimulatory or
inhibitory signals in T lymphocytes.
The CD80/CD86 (B7):CD28/CTLA-4 pathways are the best char-
acterized T cell co-stimulatory signals. It is a complex functional
axis due to the dual speciﬁcity of CD80 and CD86 for the stimula-
tory receptor CD28 as well as the inhibitory receptor CTLA-4.
CD28/B7 interactions mediate co-stimulation and signiﬁcantly en-
hance peripheral T-cell responses. In contrast, CTLA-4 activation
decreases T-lymphocyte activity and limits the immune response.
Similarly, PD-1 receptor interactions with its ligands PD-L1 and
PD-L2 down-regulate T-cell immune responses. Despite these sim-
ilarities, the regulatory roles of the CTLA-4 and PD-1 pathways are
different. This may be due, at least in part, to the differential tem-
poral and spatial expression patterns of their ligands. CTLA-4 sig-
nalling seems to be required early in the lymph node during
initiation of an immune response, while PD-1 pathway acts late
in the periphery to limit T-cell activity locally [6]. Inducible T cell
Costimulator (ICOS) has overlapping functions with CD28 in early
T-cell activation, and has emerged as an important receptor in
the immune system to regulate T-cell effector functions. In addi-
tion, ICOS plays a critical role in controlling IL-10 producing Tregs
[7].
2.2. CTLA-4
The function of CTLA-4 in the control of T cell responses is ex-
erted by synergistic actions, on effector T cells and Tregs. CD28 is
constitutively expressed on T cells and CTLA-4 is up-regulated
upon TCR activation. Such expression pattern supports that the
intrinsic role of CTLA-4 is to regulate T-cell responses after cells
have received co-stimulatory signals. The higher afﬁnity and avid-
ity of CTLA-4 for both B7 ligands compared to CD28 seems to be
critical in maintaining immune tolerance. CTLA-4 binding to B7
proteins antagonizes early T-cell activation, leading to decreased
IL-2 production, inhibition of cell cycle progression, decreased cy-
clin expression, and negative modulation of TCR signalling [8]
(Fig. 1A).
Mice deﬁcient for CTLA-4 develop a lympho-proliferative dis-
ease and die within 3–4 weeks of age [9]. This is a strong evidence
of the critical role of CTLA-4 in the inhibition of T-cell responses
and immune homeostasis. Importantly, some polymorphisms in
the CTLA-4 gene have been associated with the susceptibility to
different autoimmune diseases, including type 1 diabetes (T1D),
multiple sclerosis (MS), rheumatoid arthritis (RA), Graves’ disease,
colitis and systemic lupus erythematosus [10].
Tregs cells constitutively express high levels of CTLA-4, suggest-
ing that this molecule participates in their suppressive activity
[11]. However, normal numbers of CD4+CD25+Foxp3+Tregs cells
are found in CTLA-4-null mice [12], indicating that this molecule
is dispensable for the development, survival, and homeostasis of
Tregs lymphocytes. CTLA-4 blockade speciﬁcally affected the sup-
pression capacity of Tregs in vitro and in an experimental model
of colitis [13,14]. In addition, CTLA-4-deﬁcient Tregs inefﬁcientlycontrolled T effector responses in an adoptive transfer model of
diabetes [15].
Additionally, CTLA-4 signalling inﬂuences CD4+ T-cell differen-
tiation. CTLA-4-deﬁcient mice display T cells strongly skewed to-
wards a Th2 phenotype, even in the absence of the Th2 lineage
transcription factor signal transducer and activator of transcrip-
tion-6 (STAT6) [16]. Consistently, enhanced Th2 cell differentiation
after anti-CTLA-4 mAb injections in BALB/c mice resulted in more
severe airway inﬂammation, bronchial eosinophilia and IL-4 and
IL-5 levels in broncho-alveolar lavage following repeated allergen
inhalations. Importantly, a signiﬁcant reduction of TGF-beta syn-
thesis was detected in animals in which CTLA-4 signalling was
blocked, suggesting a potential mechanism for the regulation of
Th2 sensitization [17]. CTLA-4 also inﬂuences Th17 responses;
anti-CTLA-4 monoclonal antibodies increased Th17 differentiation
and IL-17 production both in vitro and in vivo [18]. In addition,
several studies indicate that CTLA-4 regulates the severity of pep-
tide-induced experimental autoimmune encephalomyelitis (EAE),
in mouse strains that are inherently susceptible to the disease
[19]. CTLA-4 engagement also controls disease susceptibility in
BALB/c mice, a strain considered to be resistant to EAE [20]. More-
over, CTLA-4 blockade enhances initial and ongoing experimental
autoimmune neuritis in B6 mice [21]. Thus, the CTLA-4/B7 inhibi-
tory pathway plays a critical role in the control of auto-reactivity
and the breakdown of tolerance to auto-antigens. Given its nega-
tive regulatory role, CTLA-4 is a potential therapeutic target to fos-
ter the immune response in certain pathological settings. Indeed,
CTLA-4 blockade with the monoclonal antibody ipilimumab has a
signiﬁcant therapeutic effect in patients with advanced or meta-
static melanoma, and two randomized phase III studies demon-
strated that CTLA-4 blockade prolonged overall survival in these
patients, leading to its approval by the FDA [22].
2.3. PD-1
PD-1 is induced on peripheral CD4+ and CD8+ T cells, B cells and
monocytes upon activation. PD-1 ligands have distinct patterns of
expression: PD-L1 is constitutively expressed in myeloid and lym-
phoid cells and is up-regulated upon their activation, it is also ex-
pressed in non-hematopoietic cells and in non-lymphoid organs. In
contrast, expression of PD-L2 is restricted to macrophages and DCs
in response to cytokines; PD-L2 is also expressed on bone marrow-
derived mast cells and B cells. PD-1 ligation inhibits PI3K activation
and alters membrane-proximal signalling events in T cells (Fig. 1A).
An additional tolerance mechanism of PD-1 is the promotion of
Treg development and function [23].
The role of PD-1 in immune tolerance was indicated by the
development of autoimmunity in PD-1 knock-out (KO) mice. PD-
1KOmice on a C57BL/6 background displayed arthritis and glomer-
ulonephritis [24], while the disruption of the PD-1 gene in BALB/c
mice causes dilated cardiomyopathy. High-titers of autoantibodies
against cardiac troponin I (cTnI) are detected on these animals,
which clearly indicate that PD-1 controls autoimmunity [25]. In
addition, PD-1 is critical for the maintenance of peripheral toler-
ance and the prevention of several autoimmune diseases, including
type 1 diabetes (T1D) and experimental autoimmune encephalitis
(EAE) [26,27]. Accordingly, the induction of expression of PD-L1
prevents lupus nephritis in BXSB mice [28], strongly suggesting
that engagement of the immuno-inhibitory receptor PD-1 on acti-
vated lymphocytes is able to preclude unwanted T and B cell
activation.
Human genomic studies have conﬁrmed the immunoregula-
tory role of PD-1. Thus, the single nucleotide polymorphism
(SNP) in PD-1 termed PD-1.3 is signiﬁcantly linked to develop-
ment of Systemic Lupus Erythematosus (SLE) [29], and lupus
nephritis [30]. Moreover, the same SNP has also been associated
Fig. 1. Negative regulatory molecules on the cellular membrane surface. (A) B7 family members: CTLA-4, ICOS, ICOSL, PD-1, PD-L-1 and PD-L2. CTLA-4 competes with CD28
for binding to their counter-receptors CD80 and CD86 and attenuates TCR signalling induced during Ag recognition. In addition, the engagement of CTLA-4 induces IDO
expression on APC, reinforcing its immunoregulatory effect. PD-1 signalling induced by its ligands (PD-L1 and PD-L2) expressed on APC also counteracts TCR activation,
inhibiting early proximal signalling events. Also, PD-1 can interact with PD-L1 expressed in peripheral tissues contributing to peripheral tolerance. ICOS/ICOSL pathway
regulates T-cell tolerance through the control of IL-10-producing Tregs. (B) Signalling pathways inﬂuenced by CD69 and Gal-1. CD69 is early induced following TCR activation.
The engagement of CD69 by as yet an unknown ligand activates Jak3-STAT5 pathway promoting Treg differentiation and Th17 inhibition. Gal-1 can be found on the
membrane surface linked to glycoreceptors inducing apoptosis of Th1 and Th17 cells and promoting IL-10 production. Both molecules facilitate Treg function. Green plus
symbols indicate tolerogenic signals.
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negative RA [32]. This SNP is located in an enhancer of PD-1 gene
within its fourth intron. This SNP affects the binding of the runt-
related transcription factor (RUNX-1) diminishing the expression
of this receptor [29]. In this regard, lower PD-1 receptor expres-
sion is found in SLE patients and their relatives, with a signiﬁcant
correlation with the PD-1.3A allele [33]. In addition, this PD-1
polymorphism is associated with disease progression in MS. Inter-
estingly, PD-1-mediated inhibition of T-cell cytokine secretion
(IFN-gamma) is impaired in patients carrying this PD-1 polymor-
phism [34].
Other ﬁnding that supports the role of PD-1/PD-L1 in RA is the
presence of autoantibodies against PD-L1 in sera of patients with
RA, correlating with active disease [35]. The presence of autoanti-
bodies against PD-L1 could favour the presence of defective T cell
responses in RA patients. In addition, soluble forms of PD-1 and
PD-L1 have been detected in sera and synovial ﬂuid (SF) of RA pa-
tients. The levels of soluble PD-1 signiﬁcantly correlated with those
of TNF-alpha in SF. Characterization of soluble PD-1 revealed that it
corresponded to an alternative splice variant (PD-1Deltaex3) that
could affect the regulatory function of membrane-bound PD-1 on
T cell activation [36].
Up-regulation of PD-L2, CD40 and CD86 has been detected in
patients with MS under therapy with IFN-beta. These data suggest
that modulation of positive and negative co-stimulatory signals is
part of the mechanism of action of this cytokine in MS [37]. Other
authors have reported upregulation of PD-1 and PD-L1 that results
in a higher production of IL-10 and a higher rate of apoptosis dur-
ing the quiescent phases of the MS, However, in this study, suc-
cessful therapy with IFN-beta resulted in a down-regulation of
PD-L1-expressing cells [38]. Recent studies suggest that defects
in PD-1 and its ligands participate in the immunopathogenesis of
MS. Although PD-L1 is signiﬁcantly expressed at higher levels in
MS brain lesions compared to controls, most CD8+ T lymphocytes
found in MS lesions are negative for PD-1. Moreover, while blood
vessels in normal brain tissues are PD-L2 positive, only about half
of them express PD-L2 in MS lesions. The absence of PD-1 could
render CD8+ T cells refractory to the inhibitory signal from PD-L1
expressing CNS cells [39].2.4. ICOS/ICOSL
ICOS is expressed on T cells following activation, while ICOS li-
gand (ICOSL) is detected on APC and non-hematopoietic cells.
ICOS/ICOSL pathway plays a critical role in the induction of effector
T-cells responses and in the generation of follicular helper T cells,
an important T-cell subset that promotes humoral immunity. In
this regard, blockade of ICOS/ICOSL pathways ameliorates inﬂam-
mation in several models of autoimmune diseases, such as CIA
and lupus nephritis [7]. However, recent evidence supports the role
of ICOS/ICOSL pathway in immune tolerance (Fig. 1A). Thus, it has
been described that ICOS regulates the survival of both effector-
memory T cells and FoxP3+ Treg cells during homeostasis and dur-
ing Ag-speciﬁc immune response [40]. Indeed, ICOS deﬁciency or
its blockade results in an exacerbated forms of EAE [41,42] and
T1D [43]. In addition, ICOS/ICOSL pathway has a critical role in
the induction of tolerance to allergens, by promoting the develop-
ment and function of IL-10 producing Treg cells [44]. In this regard,
it has been reported that ICOS expression identiﬁes a subset of
highly suppressive CD4+Foxp3+ Treg cells that display a suppres-
sive potential in a model of contact hypersensitivity [45], as well
as a subpopulation of intra-islet Treg lymphocytes in a T1D model
[46]. Moreover, deﬁciency of ICOS abrogated Treg-mediated func-
tions and exacerbated the disease in this model [46]. Recent data
show that Langerhans cells (LCs) are able to induce cutaneous im-
mune tolerance by a mechanism that involves the activation of
ICOS+CD4+Foxp3+Treg cells [47]. The role of ICOS in immune toler-
ance is also supported by studies with CD4+ T cells from ICOS deﬁ-
cient patients, where it has been demonstrated that the absence of
ICOS inhibits the induction of T cell anergy and differentiation into
suppressive T cells by tolerogenic DCs [48]. Beside the role of IL-10
in the function of ICOS+ Treg cells, a recent report shows that these
cells are able to suppress IL-17 production through the synthesis of
IL-35 [49].
2.5. CD69
CD69 is a type II transmembrane protein and a member of the
C-type lectin-like receptor family that is expressed in leukocytes
2900 H. de la Fuente et al. / FEBS Letters 586 (2012) 2897–2905upon stimulation [50]. It is mainly detected in the cell inﬁltrates of
several chronic inﬂammatory diseases such as RA [51]; however,
no apparent association has been detected between polymor-
phisms of CD69 and enhanced risk for this condition [52].
CD69 acts as a signal transducer in inﬂammatory processes.
Recent studies using models of inﬂammatory disease point to an
immunoregulatory role for CD69 during the immune response.
Mice lacking CD69 develop exacerbated forms of CIA [53]. Accord-
ingly, in a hapten-induced cutaneous contact hypersensitivity ro-
dent model, CD69 deletion or the administration of blocking
anti-CD69 mAb increased inﬂammation. CD69 deﬁciency also in-
duced enhanced inﬂammatory responses in animal models of aller-
gic asthma [54], autoimmune experimental myocarditis model
[55] and colitis [56]. These ﬁndings clearly establish the negative
regulatory role of CD69 in the differentiation of Th17 lymphocytes,
since these cells are major mediators of these conditions.
Molecular studies identiﬁed that CD69 promotes activation the
Jak3-STAT5 signalling pathway, thereby inhibiting Th17 cell differ-
entiation [57] (Fig. 1B). Taken together all these studies establish
that CD69 is an intrinsic negative modulator of T cell responses
[58]. In addition, this molecule may also have an important role
in the generation and activity of T reg cells.
Several in vivo studies also suggest a possible role for CD69 in
the regulation of immune cell migration. Constitutive CD69
expression in transgenic mice identiﬁed a potential role for CD69
in the control of thymocyte export [59]. A subsequent report has
shown that CD69 can form a complex with the sphingosin-1 phos-
phate S1P receptor in T lymphocytes, promoting its down-regula-
tion and inducing lymphocyte retention in lymphoid organs [60].
Likewise, DCs migration from the periphery towards lymph nodes
is signiﬁcantly increased in CD69-deﬁcient mice, indicating its role
as a negative regulator of chemoattractant-directed migration [61].
Although CD69 was generally regarded as one of the markers of
Treg cells; recent studies suggest that this molecule may exert a
signiﬁcant role in their immunosupressive activity. In this regard,
in patients with systemic sclerosis has been described a dimin-
ished function of Treg cells which is associated with a diminished
expression of CD69 and a defective synthesis of TGF-beta [62]. In
addition, a new subset of CD69(+)CD4(+)CD25() Treg cells, has
been recently identiﬁed in mice bearing tumors. These cells do nei-
ther express Foxp3 expression nor synthesize IL-10, but show high
expression of CD69 and membrane-bound TGF-beta1 and help tu-
mors to scape from immune surveillance [63]. These regulatory T
cells increase dramatically along tumor progression, and mediate
suppression of T cell proliferation through TGF-beta1. Further-
more, engagement of CD69 maintains high expression of mem-
brane-bound TGF-beta1 on CD69(+)CD4(+)CD25() T cells via
ERK activation. These novel regulatory cells have been identiﬁed
in patients; their occurrence is associated to reduced risk of acute
graft-versus-host disease after allotransplants in humans [64].
Most recently, tumor-derived CD69(+) T cells have been found to
induce an increase of IDO expression in monocytes. This consti-
tutes a potential mechanism of negative crosstalk between innate
and adaptative immune cells, that may contribute to immune sur-
veillance evasion by tumor cells [65].
2.6. Galectins
Galectins are a family of highly conserved glycan-binding pro-
teins. Although, galectins were initially described to mediate
developmental processes, it is now clear that some members of
this family of proteins have an essential role in the development
of innate and adaptive immune responses. Galectins are expressed
both intracellular and extracellularly; once secreted galectins can
be found on the membrane surface because their binding to glyco-
receptors [66]. Three galectins in particular have been extensivelystudied, due to their ability to modulate adaptive immune re-
sponses: galectin (Gal)-1, Gal-3 and Gal-9.
Galectin-1 (gal-1) acts as a negative regulator of the inﬂamma-
tory response. Different in vitro functions mediated by gal-1 such
as the promotion of apoptosis of Th1 cells, induction of IL-10 and
downregulation of pro-inﬂammatory cytokines result in limiting
the immune response [66,67] (Fig. 1B). Administration of exoge-
nous gal-1 induces immunosuppression and counters inﬂamma-
tion in various experimental models of inﬂammation and
autoimmunity such as inﬂammatory bowel disease (IBD), autoim-
mune retinal disease, autoimmune diabetes or CIA [66]. In a rodent
model of CIA, overexpression of gal-1 induces higher levels of anti-
gen-induced T-cell death in lymph nodes from arthritic rats and
signiﬁcantly reduces the joint index scores [68]. In addition, gal-1
deﬁciency exacerbated Th1 and Th17 responses and enhanced
susceptibility to autoimmune neuroinﬂammation [66]. Gal-9
downregulates Th1 and Th17 responses in models of skin inﬂam-
mation through its interaction with TIM-3, a Th-1 speciﬁc cell sur-
face molecule [69]. Different models of inﬂammatory diseases,
such as immune complex-induced arthritis or diabetes, support
the anti-inﬂammatory properties of gal-9 [70,71].
Data regarding expression or function of galectins in human
autoimmune diseases is scarce. Circulating autoantibodies against
gal-1 have been found in SLE patients [72]. Although the patholog-
ical signiﬁcance of this ﬁnding is unclear, it is conceivable that
antibodies against gal-1 could block its regulatory functions exac-
erbating inﬂammation in this pathology. A very recent study re-
ports a clear down-regulation of gal-1 in Langerhans and dermal
DCs in both lesional and uninvolved skin from psoriasis patients
as well as on myeloid peripheral DCs [73]. Skin mRNA levels of
gal-1 correlated with IL-17 and IL-10 mRNA levels [73]. Based on
these data, a model can be proposed in which gal-1 expression
and ligand engagement limit skin inﬂammatory responses, sug-
gesting that gal-1 downregulation in human DCs may contribute
to the exacerbation of the inﬂammatory response observed in
psoriasis.3. Signalling molecules: SOCS and GADD45 family members
3.1. SOCS
Cytokines signal through receptor oligomerization, which initi-
ates activation of associated Janus kinases (JAKs) [74]. Activated
JAKs phosphorylate the cytoplasmic domains of the triggering
receptors, creating docking sites for SH2-containing signalling pro-
teins. This result in the phosphorylation and dimerization of STATs,
which then translocate to the nucleus and initiate gene transcrip-
tion. SOCS proteins are important negative regulators of cytokine
signalling (Fig. 2A). SOCS proteins have a central SH2 domain;
through this domain, they block STAT recruitment to the cytokine
receptor; SOCS also target receptors and JAKs for their degradation
by the proteasome. In addition, SOCS-1 and SOCS-3 can inhibit JAK
tyrosine kinase activity through their kinase inhibitory region.
SOCS protein transcription is induced by several cytokines, but also
by other soluble mediators not speciﬁc for lymphocytes. The gen-
eral biology of SOCS has been reviewed elsewhere [75]. SOCS-1
and SOCS-3 are the most important members of this family in
the regulation of innate and adaptive immune responses.
SOCS-3 is heavily phosphorylated in the synovial tissue of RA
patients compared to tissues from patients with a non-inﬂamma-
tory, degenerative form of arthritis. Forced expression of SOCS3
in RA-derived synoviocytes inhibits synovial ﬁbroblast prolifera-
tion and IL-6 production [76]. Studies in rodent models of arthritis
have highlighted the role of SOCS3 in the regulation of inﬂamma-
tory response in this pathology. Local injection of adenovirus
Fig. 2. Intracellular regulatory molecules. (A) SOCS proteins interfere with Jak-STAT pathways induced by the interleukin receptors. SOCS-3 blocks STAT3 recruitment and
reduces IL-6 and IL-17 expression. SOCS-1 is a negative regulator of Th1 response through the inhibition of STAT-1 activation. Signalling pathway of p38 is involved in
proinﬂammatory cytokines expression. Beside the classical pathway of p38 activation mediated by MAPK, T-cells show an alternative route that is speciﬁcally inhibited by
Gadd45a. (B) IDO is expressed mainly on DCs and macrophages. Its expression is regulated by several signals, including the engagement of B7 molecules by CTLA-4.
Tryptophan (TRP) catabolism by IDO activity counteracts T cell activation by two mechanisms: TRP-induced starvation and by the production of proapoptotic metabolites,
named kynurenines. After binding to its ligands (i.e. kynurenines) AhR is translocated to the nucleus where forms a complex with ARNT which induces its binding to dioxin
response elements (DRE) promoting the expression of IL-10 and IL-22. In addition, AhR activation blocks STAT-1 and STAT-5 and downregulates Th17 differentiation. AhR
activation also induces IL-10 expression on APC. Green plus symbols indicate tolerogenic signals.
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prevents development of the disease; in a CIA model, local expres-
sion of SOCS-3 after establishment of the disease blocks its pro-
gression [76]. Mice lacking SOCS-3 in the hematopoietic and
endothelial compartments develop severe acute inﬂammatory
arthritis characterized by elevated inﬁltration of neutrophils in
the synovium, bone marrow, peripheral blood and spleen. In this
model, SOCS-3 negatively regulates CD4+ T lymphocyte activation
including production of IL-17 and osteoclast generation [77].
Also, SOCS1 has emerged as an important negative regulator of
Th1 cells as revealed in T cell-speciﬁc SOCS-1 conditional KO mice
[78] and Th1 hyperactivation promoted by SOCS1-deﬁcient DCs
[79]. However, SOCS1 could have a more limited role in joint
inﬂammation compared with SOCS3. In the model of acute inﬂam-
matory arthritis SOCS1/ develop more severe arthritis with an
increased number of macrophages in the synovium. These animals
also exhibit a small increase in synovial neutrophils numbers and
osteoclast-mediated bone destruction, whereas the opposite was
observed in SOCS3 KO mice [77]. Also, SOCS1 polymorphisms have
been associated with adult asthma [80] and MS [81]. The possible
role of SOCS1 in the development of asthma has been also high-
lighted using mouse models of allergic airway disease [82]. SOCS1
inactivation induced airway hyperresponsiveness after IL-13 treat-
ment, and in an OVA-induced model induction of SOCS1 in the air-
ways attenuated allergen-induced responses [82]. Interestingly,
this study also showed that airway muscle cells from individuals
with asthma had an impaired up-regulation of SOCS-1 after IL-13
stimulation [82]. Both SOCS-1 and SOCS-3 have also been impli-
cated in the regulation of inﬂammation of CNS (reviewed in [83]).
3.2. GADD45
Members of the GADD45 (growth arrest and DNA damage-
inducible genes) family proteins are involved in many key biolog-
ical processes such as cell growth, differentiation and apoptosis.
Three members of this family have been identiﬁed in mammaliancells: Gadd45a, Gadd45b, and Gadd45g. Mounting evidence indi-
cates that Gadd45 family members have important functions in T
cells. Gadd45b deﬁciency in CD4+ T cells impairs their responses
to TCR stimulation or inﬂammatory cytokines [84]. Moreover,
Gadd45b KO dendritic cells (DCs) show reduced IL-12 and IL-6 pro-
duction, and Gadd45b-deﬁcient mice show an impaired Th1 re-
sponse [84]. Gadd45-b also antagonizes TNF-alpha cytotoxicity
by suppressing TNF induced c-Jun N-terminal kinase activation.
Although neither Gadd45b nor Gadd45g are expressed in naïve T
cells, both are up-regulated in response to T cell activation or stim-
ulation with IL-12. Also, there is evidence that Gadd45b is involved
in IL-12 and IL-18-induced IFN-gamma production [85]. Gadd45 g
expression is higher in Th1 cells than in Th2 cells. Th1 cells from
Gadd45g KOmice are severely compromised in their ability to acti-
vate p38 and JNK in response to TCR signalling; and produce de-
creased levels of IFN-gamma upon re-stimulation [86]. In
contrast to the other two family members, Gadd45a is expressed
in resting T cells as well as many other tissues. In the immune con-
text, Gadd45a has been described as a negative regulator of activa-
tion-induced T cell proliferation. p38 is a well-characterized
mediator of signal stress, including pro-inﬂammatory molecules
such as TNF-a and IL-1. Importantly, p38 is also activated in re-
sponse to TCR signalling and participates in Th1 differentiation
[87]. The mechanism of p38 activation involves the phosphoryla-
tion cascade of classic MAPK pathway. In T cells, p38 is also acti-
vated by an alternative mechanism in response to TCR signalling
[88] that is negatively modulated by Gadd45a (Fig. 2A) [89].
Gadd45a KO mice spontaneously develop an autoimmune disease
remarkably similar to human systemic lupus erythematosus [90].
Activation of the alternative pathway of p38 triggering has been re-
cently found in patients with active RA compared with patients in
remission. However, no signiﬁcant differences in Gadd45a expres-
sion were found between patients with active RA or in remission
[91]. This study establishes the importance of the alternative p38
pathway in T cell activation in RA patients and points out the
possible inhibition of this pathway as a therapeutic target to
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Gadd45 family members warrant research to elucidate their role
in the immunopathogenesis of autoimmune diseases.4. Intracellular molecules: IDO and AhR
4.1. IDO
IDO is a cytosolic enzyme that catalyzes the rate-limiting step in
the catabolism of the essential amino acid tryptophan (TRP). Tryp-
tophan sequestration by up-regulation of IDO is one of the mecha-
nisms involved in the suppression of the immune response via T
cell starvation [92] (Fig. 2B). IDO activation induces the production
of proapoptotic tryptophan metabolites known as kynurenines
(Fig. 2B). IDO expression and its enzymatic activity are tightly con-
trolled; IDO is induced by IFNs released in response to inﬂamma-
tion in several cell types, such as DCs, macrophages, eosinophils
or endothelial cells. In addition, other molecules with negative
immunoregulatory functions such as CTL4-A or 4-1BB (CD137)
control IDO expression (Fig. 2B). The immunoregulatory effects of
IDO are mainly mediated by DCs and involve not only tryptophan
deprivation but also production of kynurenines. Although some
evidence supports the possible involvement of IDO in regulating
Th2 responses, the majority of data indicate that the immunosup-
pressive effect of IDO is mainly exerted on Th1 cell-mediated
immune responses [92].
An early study suggested that IDO participates in controlling fe-
tal allograft rejection in mice [93]. Since then, a number of studies
support the importance of IDO as a negative costimulatory mole-
cule. Use of pharmacologic inhibitors of IDO and tryptophan
metabolites or its derivatives have revealed the key role of IDO
in several autoimmune inﬂammatory diseases. In vitro, IDO is in-
duced in microglia upon treatment with IFN-gamma. During the
course of EAE, both IDO expression and its activity are up-regu-
lated. Furthermore, inhibition of IDO activity by the speciﬁc inhib-
itor 1 methyl tryptophan exacerbates the disease [94]. As stated
above, kynunerines are tryptophan metabolites that participate
in immunosuppresion induced by IDO. Treatment with synthetic
tryptophan metabolites inhibits proliferation of myelin-speciﬁc T
cells and production of Th1 cytokines and reverses paralysis in
mice with EAE [95]. Recently, IDO deﬁciency has been shown to
promote T cell responses, down-regulate Treg responses, and
enhance EAE severity [96]. In contrast, tryptophan metabolite
3-hydroxyanthranillic acid (3-HAA) promoted Treg function
in vitro, and administration of 3-HAA in mice reduced the severity
of EAE [96]. We conclude that local expression of IDO during brain
inﬂammation may constitute a self-protection mechanism that
limits antigen-speciﬁc immune responses in the CNS.
The role of IDO as a negative regulator of the inﬂammatory
response has also been observed in other animal models of autoim-
mune disease. In CIA, which is primarily mediated by a Th1-like
immune response, IDO activity is increased and its inhibition
results in an exacerbated Th1 response [97]. Furthermore, IDO-
deﬁcient mice show an exacerbated CIA severity that correlates
with an increased production of IFN-gamma and IL-17 by lymph
node T cells, and increased inﬁltration of Th1 and Th17 cells in
the affected joints [98]. Recently, bone marrow-derived DCs trans-
duced with IDO and the exosomes they produce were assayed for
their immunosuppressive ability in CIA. Both DCs and exosomes
derived from IDO+ DCs displayed anti-inﬂammatory properties
[99]. In addition, intra-articular delivery of IDO gene ameliorated
arthritis of CIA rats by induction of CD4+ T cells apoptosis and
reduction of IL-17 production [100].
Although toll-like receptors (TLR)s were initially considered as
stimulatory molecules capable of activating defence mechanismsagainst invading pathogens, emerging evidence suggests that they
can also exert a regulatory function. Administration of TLR ligands
induces high levels of IDO, and TLR9 ligand-induced pulmonary
IDO activity inhibits Th2-driven experimental asthma [101]. IDO
activity expressed by resident lung cells, rather than pulmonary
DCs, suppressed lung inﬂammation and airway hyperreactivity
[101]. The function of the TLR/IDO axis has been observed in two
additional models of autoimmune diseases, experimental autoim-
mune diabetes [102] and experimental colitis [103].
Tolerance to self-antigens present in apoptotic cells is critical to
maintain immune-homeostasis and prevent systemic autoimmu-
nity. A recent study reports that systemic administration of apop-
totic cells to mice induces IDO expression. Also, chronic exposure
of IDO-deﬁcient mice to apoptotic cells induced a lupus-like dis-
ease. In this scenario, IDO inhibition increased T cell response to
apoptotic cell-associated antigens and accelerated disease progres-
sion in lupus-prone MRL mice [104].
Regarding human autoimmune diseases, increased TRP degra-
dation has been observed in the blood of RA patients, and the
decrease in the TRP level correlates with the severity of the disease
[105]. However, decreased levels of IDO-expressing peripheral
blood mononuclear cells from RA patients has been recently
described [106]. DCs derived from joint synovial ﬂuid from RA
patients express IDO that is fully functional and thus able to catab-
olize tryptophan. However, synovial auto-reactive T cells from
these patients are resistant to IDO-mediated inhibition. Enhanced
expression of tryptophanyl-tRNA-sythetase (TTS) in T cells was
responsible for their resistance to IDO-mediated tryptophan depri-
vation [107]. TTS is a constitutively expressed cytoplasmic enzyme
able to bind tryptophan with its speciﬁc tRNA [108]. The trypto-
phan/tRNA complex constitutes a reservoir of tryptophan for
protein synthesis that can antagonize IDO-mediated immunosup-
pression by tryptophan deprivation.
Data regarding the induction of IDO and the subsequent synthe-
sis of kynurenines in MS patients is lacking. Early studies reported
the tryptophan degradation and the activation of the kynurenine
pathway in MS in the plasma and cerebrospinal ﬂuid (CSF) of MS
patients [109]. Additional studies conﬁrmed these data, describing
low concentrations of TRP in serum and CSF from patients with
chronic MS [110]. In primary biliary cirrhosis patients, defects in
IDO expression have also been observed, which correlated with
an increased frequency of a gain-of-function SNP within the TGF-
beta promoter region, a molecule known to suppress IDO tran-
scription [111]. However, increased IDO activity is associated with
the severity in other diseases such as SLE [112]. Likewise, lesional
skin from psoriasis patients expresses higher levels of IDO mRNA
compared with non-lesional skin [113]. Myeloid DCs (CD11c+,
CD68) are major vehicles of IDO expression in psoriasis.[114]
However, IDO up-regulation in psoriasis is not enough to surpass
the inﬂammatory response in these patients. Therefore, it would
be interesting to test the activity of the enzyme in these patients
and the susceptibility of inﬂammatory cells to IDO activation.
4.2. AhR
Aryl hydrocarbon receptor (AhR) is a ligand-activated transcrip-
tion factor. AhR is an important transcriptional regulator of drug
metabolizing enzymes, best known for mediating the toxicity of di-
oxin. It is well established that dioxin and other related com-
pounds cause immunosuppression and thymic atrophy. AhR also
has endogenous functions that include controlling cell cycle, im-
mune responses and cell differentiation. In the absence of ligand,
AhR is located in the cytoplasm and forms a complex with several
proteins including the chaperone protein hsp90. Ligand binding in-
duces a conformational change in AhR, which facilitates its translo-
cation to the nucleus, dissociation from the chaperone proteins and
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translocator). The resulting complex binds to regulatory sequences
termed dioxin responsive element (DRE) that eventually results in
transcription of target genes [115] (Fig. 2B). In addition to environ-
mental chemicals or xenobiotics as dioxin, AhR can be activated by
endogenous ligands such as 6-formylindolo[3,2-b]carbazole (FICZ),
bilirubin, or the eicosanoid Lipoxin A4 [115]. Interestingly, kynu-
renine (the downstream metabolite of IDO activity) is an AhR ago-
nist [116] (Fig. 2B). Moreover, IDO is induced by DCs in response to
dioxin [117] and AhR deﬁcient LCs do not express IDO [118].
AhR is differentially expressed in different lymphocyte subsets.
Th17 cells and DCs express high levels of AhR. Some of the effects
of AhR activation in the immune system are: modulation of the
Th1/Th2 balance [119], generation of regulatory T cells [120] and
regulation of Treg and Th17 cell differentiation [121].
Studies in animal models have revealed the regulatory role of
AhR in inﬂammatory diseases. Activation of AhR by FICZ, a high-
afﬁnity ligand for AhR during EAE induction exacerbated the dis-
ease by promoting Th17 cell differentiation [121,122]. In contrast,
administration of dioxin increases Treg activity and proliferation,
and suppresses EAE. It is therefore conceivable that, depending
on the ligand, AhR is capable of regulating both Treg and Th17 cell
differentiation [121]. On the other hand, induction of CIA in AhR
deﬁcient mice results in reduced levels of pro-inﬂammatory cyto-
kines and generation of Th17 cells. This effect depends on the pres-
ence of AhR in T cells because lack of AhR speciﬁcally in T cells
signiﬁcantly suppressed the development of CIA, whereas AhR
deﬁciency in macrophages had no effect [123]. Regarding to Th17
regulation, it has been reported that AhR interacts with both
STAT-1 and STAT-5, and regulates the activation of STAT1 during
Th17 polarization conditions [124], which negatively regulates
Th17 differentiation (Fig. 2B).
AhR could have an important role in the maintenance of im-
mune barriers. AhR deﬁcient mice display impaired skin gamma/
delta T cell proliferation, which are essential to the LCs maturation
in the skin [118,125]. Recent observations also shown that AhR
regulates gut immunity by promoting the function of innate lym-
phoid cells as well as IL-22 production [126]. Interestingly, intes-
tine tissue from patients with inﬂammatory bowel diseases
express signiﬁcantly less AhR compared to control cells [127].
Although more studies are necessary to elucidate the importance
of AhR in IBD, these data indicate that this intracellular receptor
may play a key role the immunopathogenesis of gut inﬂammation.
5. Concluding remarks
Whereas the immunological mechanisms that promote inﬂam-
mation during autoimmune inﬂammatory diseases are relatively
well characterized, the speciﬁc mechanisms that down-modulate
inﬂammatory responses are poorly understood.
For many years the therapy of autoimmune inﬂammatory
diseases was based in the use of anti-inﬂammatory compounds
(mainly glucocorticoids) and non-selective cytotoxic immunosup-
pressive drugs (cyclophosphamide, azathioprine, etc.). In the
recent years, the identiﬁcation of different receptors and intracel-
lular molecules that exert a key role in the activation of immune
cells has allowed the development of more selective immunosup-
pressive drugs (tacrolimus, sirolimus) as well as the generation of
different biological agents that are able to eliminate immune cells
(e.g., anti-CD20 agents) or to interfere with the action of proinﬂam-
matory cytokines (e.g., TNF-a blocking agents). However, in some
cases these approaches are not exempt of risk.
In the last years the study of molecules with negative
co-stimulatory activity has revealed the importance of tolerance
signals in the pathogenesis and progression of these diseases andnew targets are now under intensive research. It is evident that
additional therapeutic agents are necessary for the treatment of
autoimmune/inﬂammatory conditions. In this regard, the recent
advances in the knowledge of the different immunoregulatory
molecules reviewed herein, will allow the identiﬁcation of novel
therapeutic targets, with the subsequent development of addi-
tional immunosuppressive and highly selective agents. Further-
more, the characterization of the receptors and intracellular
molecules involved in the generation and activation of Treg cells
will be very useful for the design of novel strategies of immuno-
suppression. These molecules not only dampen pro-inﬂammatory
signals but also promote both generation and function of Treg cells.
Further studies are necessary to unravel strategies to potentiate or
improve their function.Acknowledgments
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